Acute disseminated encephalomyelitis and COVID-19: A systematic synthesis of worldwide cases

Laura Zelada-Ríos, Kevin Pacheco-Barrios, Milagros Galecio-Castillo, Cesar Yamunaqué-Chunga, Kelvin Álvarez-Toledo, Ricardo Otiniano-Sifuentes

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Acute disseminated encephalomyelitis (ADEM) has been reported after coronavirus disease 2019 (COVID-19). In this review, we systematically included worldwide reported cases on this association. We included 30 case reports (pediatric and adults) and explored epidemiological and clinical evidence. We described time to diagnosis, clinical, imaging, and laboratory features, response to treatment regimens, and differences regarding severity. Also, an original case report was presented. Neurologists must be alert to the occurrence of multifocal neurological symptoms with or without encephalopathy in patients recovered from COVID-19. Timely MRI studies should be performed to establish the diagnosis and to consider early corticosteroid-based treatment.

Original languageEnglish
Article number577674
Pages (from-to)577674
JournalJournal of Neuroimmunology
StatePublished - 15 Oct 2021


  • Acute disseminated encephalomyelitis (ADEM)
  • Autoimmune disease
  • Central nervous system (CNS)
  • Coronavirus disease 2019 (COVID-19)
  • Demyelinating disease
  • SARS-Cov-2
  • COVID-19/complications
  • Global Health
  • Humans
  • Male
  • Methylprednisolone/therapeutic use
  • Observational Studies as Topic/methods
  • Adult
  • Encephalomyelitis, Acute Disseminated/diagnostic imaging


Dive into the research topics of 'Acute disseminated encephalomyelitis and COVID-19: A systematic synthesis of worldwide cases'. Together they form a unique fingerprint.

Cite this